Efficacy and Safety of keepMED Positive Airway Pressure Device in Patients With Obstructive Sleep Apnea (keePaOSA)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04875897 |
|
Recruitment Status :
Not yet recruiting
First Posted : May 6, 2021
Last Update Posted : September 2, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
A prospective, multi-centre, single-arm, open-label, interventional study with a non-marketed medical device.
The primary study objective is to assess the efficacy of the keepMED PAP device on modification of respiratory characteristics in patients with OSA at one therapy night in a sleep lab.
Secondarily, the safety of the use of the device in this setting is assessed.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Obstructive Sleep Apnea | Device: keepMED PAP device | Not Applicable |
The study includes a baseline visit, a habituation night, and a therapy night. Both nights will be undertaken in the sleep lab under identical conditions and will include the keepMED PAP therapy activated in parallel to polysomnography (PSG).
Baseline diagnostic PSG, performed within one month prior to enrollment to the study, will be used to assess the device efficacy.
An interim analysis to re-estimate the sample size will be performed after availability of data of 50% enrolled and treated study patients. The sample size will be re-estimated based on the observed changes of AHI in the interim analysis.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 65 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Intervention Model Description: | Each subject serves as his/her own control |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | KeepMED-away-Obstructive Sleep Apnea Trial: Efficacy and Safety of keepMED Positive Airway Pressure Device in Patients With Obstructive Sleep Apnea - keePaOSA |
| Estimated Study Start Date : | September 14, 2021 |
| Estimated Primary Completion Date : | January 15, 2022 |
| Estimated Study Completion Date : | February 28, 2022 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: treatment with keepMED PAP device
Therapy night is performed with the keepMED PAP during a polysomnography in the sleep lab
|
Device: keepMED PAP device
The keepMED PAP device is an automatic, wearable positive airway pressure device indicated for treatment of obstructive sleep apnea. A therapeutic pressure is delivered to the patient upper airway through a nasal interface. It is similar to other marketed positive airway pressure devices with respect to its fundamental use of positive airway pressure for the treatment of sleep apnea as well as with regard to its functional components and accessories (e.g., a PAP unit, a mask/nasal interface, an air filter, tubing, etc.). |
- Changes of Apnea Hypopnea Index (AHI) [ Time Frame: A single therapy night compared to baseline (conducted approx 1 month before the therapy night) ]Efficacy by means of changes of the AHI comparing baseline measures in a sleep lab night without keepMED PAP therapy with measures during one therapy night in a sleep lab.
- Changes in oxygen desaturation index (ODI) [ Time Frame: A single therapy night compared to baseline (conducted approx 1 month before the therapy night) ]Changes in ODI comparing baseline measures in a sleep lab night without keepMED PAP therapy with measures during one therapy night in a sleep lab
- Changes in arousal index (sleep quality) [ Time Frame: A single therapy night compared to baseline (conducted approx 1 month before the therapy night) ]Changes in arousal index comparing baseline measures in a sleep lab night without keepMED PAP therapy with measures during one therapy night in a sleep lab
- Number of adverse events [ Time Frame: Throughout the study, an average of 2-7 days per subject ]Safety of the device use by means of adverse events in patients using the keepMED PAP device
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Age ≥18 years.
Newly diagnosed OSA with AHI ≥ 15 events/hours.
Indication for OSA PAP therapy in routine clinical care according to applicable medical guidelines within one month prior to study enrolment.
Naïve to PAP therapy, i.e. even no PAP therapy during a PSG night.
Weight > 30kg.
Signed informed consent.
Exclusion Criteria:
Body Mass Index (BMI) of ≤20 kg/m² or ≥ 35 kg/m².
Pathologically low blood pressure (systolic ≤90mm Hg; diastolic ≤60 mm Hg).
Current unstable or serious medical conditions (such as angina pectoris, myocardial infarction, cancer, stroke, dementia, congestive heart failure) which based on the physician's judgment might put the patient at high risk.
Mixed and central apnea index ≥ 5 events/hour in PSG without PAP therapy.
Bullous lung disease.
Tracheostomy.
Pneumothorax.
Pneumocephalus.
Cerebrospinal fluid leak.
Current sinus or middle ear infection.
Persistent blockage of one or both nostrils (including nasal septum deviation and nasal polyps) or any other reason that leads to difficulty of breathing through the nose while awake.
Any nasal, facial or head abnormalities that would not allow adequate placement of the device.
Previous diagnosis of insomnia, narcolepsy or periodic limb movement disorder that in the judgment of the clinician could affect sleep quality assessment.
Chronic respiratory disease (COPD, pulmonary fibrosis or asthma) or FEV/FVC ≤ 60% in history.
History of respiratory failure.
Supplemental oxygen is required.
Uvulopalatopharyngoplasty or other surgical procedure to correct apnea.
Acute respiratory infection.
Subject recovered from Covid-19 but suffers from on-going symptoms or when subject's Covid-19 illness history can affect the study outcome based on the physician's judgment.
Pregnancy.
Medication that may alter sleep architecture.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04875897
| Contact: Pierre-Charles Neuzeret, PhD | +49 152 554 22500 | pierre-charles@keepmed.com | |
| Contact: Alex Rapoport | +972 3 5170837 | alex@keepmed.com |
| Principal Investigator: | Jean-Louis Pépin, Prof | CHU Michallon Laboratoire EFCR CS 10217 |
| Responsible Party: | keepMED Ltd. |
| ClinicalTrials.gov Identifier: | NCT04875897 |
| Other Study ID Numbers: |
CLN-210423-00 |
| First Posted: | May 6, 2021 Key Record Dates |
| Last Update Posted: | September 2, 2021 |
| Last Verified: | May 2021 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | No |
|
Apnea Sleep Apnea Syndromes Sleep Apnea, Obstructive Respiration Disorders Respiratory Tract Diseases |
Signs and Symptoms, Respiratory Sleep Disorders, Intrinsic Dyssomnias Sleep Wake Disorders Nervous System Diseases |